Last reviewed · How we verify
zoledronic acid (aclasta)
At a glance
| Generic name | zoledronic acid (aclasta) |
|---|---|
| Also known as | aclasta |
| Sponsor | Seoul National University Bundang Hospital |
| Modality | Small molecule |
| Phase | Phase 3 |
Approved indications
Common side effects
Key clinical trials
- Romosozumab as an Adjunct to Physiologic Estrogen Replacement in Functional Hypothalamic Amenorrhea (PHASE3)
- Zoledronic Acid Treatment in Patients With Congenital Dyserythropoietic Anemia (PHASE1, PHASE2)
- Alpha/Beta T and B Cell Depletion With Zoledronic Acid for Solid Tumors (PHASE1, PHASE2)
- Bone Loss Prevention With Zoledronic Acid or Denosumab in Critically Ill Adults (PHASE2)
- Zoledronate In the Prevention of Paget's Disease: Long Term Extension
- Romosozumab Use to Build Skeletal Integrity (PHASE4)
- Contribution of Bone to Urine Citrate
- The Comparison of Ibandronate and Zoledronic Acid After Denosumab Discontinuation (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- zoledronic acid (aclasta) CI brief — competitive landscape report
- zoledronic acid (aclasta) updates RSS · CI watch RSS
- Seoul National University Bundang Hospital portfolio CI